Assoc Prof Mark Smythe is the co-founder of Infensa Bioscience and a serial entrepreneur with a track record of founding five biotechnology companies. He has significant drug development experience, including one marketed drug and six constrained peptides that have progressed to clinical trials. His recent successes include two Phase 3 programs—rusfertide and icotrokinra. In addition to his scientific achievements, he brings extensive commercial expertise, having led numerous deals with major pharmaceutical companies. He is also the founder of Protagonist Therapeutics, which reached a market capitalisation of AUD 5 billion as of March 2025.